SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes

Stich, Oliver; Klages, E.; Bischler, P; Jarius, Sven; Rasiah, Christiane; Voltz, Raymond; Rauer, Sebastian

doi:10.1111/j.1600-0404.2011.01572.x

Cited by 40 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,18 Until now, little has been known about the prevalence and underlying pathogenesis of NSCLC and anti-SOX1-abs-related PNS. Our study found that only 22 patients with anti-SOX1 abs had NSCLC corresponding to other histological types, which were described as squamous-cell cancer (n= 6), 17,19 adenocarcinoma (n=7), 19,21 bronchial carcinoid (n=1), 46 polymorphic NSCLC (n=1), 21 and unspecified NSCLC (n= 7) (Table 3). 6,12,20 We found that anti-SOX1 abs in patients with NSCLC of mediastinal squamous-cell carcinoma con-JCN Table 2.…”

Section: Coexisting Tumorsmentioning

confidence: 82%

“…6,12,20 We found that anti-SOX1 abs in patients with NSCLC of mediastinal squamous-cell carcinoma con-JCN Table 2. Anti-SOX1-abs-related clinical characteristics Ruiz-García et al (2/71), 12 Titulaer et al (2/72), 11 Titulaer et al (6/65), 49 Stich et al (2/8), 21 Dogan Onugoren et al (2/3), 20 Tschernatsch et al (4/9), 46 Sabater et al (1/62), 7 Saraya et al Lancaster et al 99 also reported a 70-year-old male patient with SOX1, GABABR, and…”

Section: Coexisting Tumorsmentioning

confidence: 99%

“…Abnormal DNA methylation of the promoter region of SOX1 is a potential pathogenesis. 19,62 Notably, a small group (n=34, 6.5%) of the 520 patients with anti-SOX1 abs developed neurological symptoms without underlying tumors, 7,11,12,18,20,21,25,45,46,49,63 even after years of follow-up, but the mechanism that triggered the autoimmune response remains unknown. A possible explanation is that the tumor was too small to be detected or would have developed in the future.…”

Section: Jcnmentioning

confidence: 99%

“…16 However, the understanding of the underlying mechanism of non-SCLC (NSCLC)-associated PNS is hindered by the rarity of the cases, with only a few studies described NSCLC patients presenting with anti-SOX1 abs. 12,[17][18][19][20][21] Since PCD is considered the most common PNS, we reviewed the neuronal autoabs and associated tumors present-ing as PCD (Table 1). In addition, we critically reviewed the clinical features of 486 cases of anti-SOX1 abs with identified tumors in 32 English-language and 4 Chinese-language studies reported up to December 2019 (Tables 2 and 3).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome

et al. 2020

View full text Add to dashboard Cite

Anti-Sry-like high mobility group box (SOX) 1 antibodies (abs) are partly characterized onconeural autoantibodies (autoabs) due to their correlation with neoplastic diseases. Anti-SOX1 abs are associated with various clinical manifestations, including Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar degeneration (PCD). However, the clinical characteristics of patients with anti-SOX1 abs have not been described in detail. This review systematically explores the reported patients with anti-SOX1 abs and analyzes these cases for demographic characteristics, clinical features, coexisting neuronal autoabs, neuroimaging findings, treatment, and clinical outcomes. In addition, considering that PCD is the most common paraneoplastic neurological syndrome and that the association between PCD and anti-SOX1 abs remains unclear, we focus on the presence of autoabs in relation to PCD and associated tumors. PCD-associated autoabs include various intracellular autoabs (e.g., anti-Hu, anti-Yo, anti-Ri, and anti-SOX1) and cell-surface autoabs (anti-P/Q-type voltage-gated calcium channel). Commonly involved tumors in PCD are small-cell lung cancer (SCLC), gynecological, and breast tumors. LEMS is the most common clinical symptom in patients with anti-SOX1 abs, followed by PCD, and multiple neuronal autoabs coexist in 47.1% of these patients. SCLC is still the predominant tumor in patients with anti-SOX1 abs, while non-SCLC is uncommon. No consistent imaging feature is found in patients with anti-SOX1 abs, and there is no consensus on either the therapy choice or therapeutic efficacy. In conclusion, the presence of anti-SOX1 abs alone is a potential predictor of an uncommon paraneoplastic neurological disorder, usually occurring in the setting of LEMS, PCD, and SCLC. The detection of anti-SOX1 abs contributes to an early diagnosis of underlying tumors, given the diversity of clinical symptoms and the absence of characteristic neuroimaging features.

show abstract

Section: Coexisting Tumorsmentioning

confidence: 82%

Section: Coexisting Tumorsmentioning

confidence: 99%

Section: Jcnmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Anti-SOX-1 antibodies are also detected in Lambert-Eaton syndrome with SCLC [ 12 , 13 ]. SOX1 reactivity is predominantly associated with anti-Hu antibodies and SCLC [ 14 ]. Anti-Hu and SOX-1 antibodies target intracellular antigens [ 1 , 5 , 12 ], while anti-gAchR antibodies target cell surface antigens [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

Integrated treatment for autonomic paraneoplastic syndrome improves performance status in a patient with small lung cell carcinoma: a case report

et al. 2018

View full text Add to dashboard Cite

BackgroundParaneoplastic neurological syndromes (PNS) are rare disorders associated with cancer and are believed to be immune mediated. Patients with autonomic PNS suffer from variable combinations of parasympathetic and sympathetic failure. Autonomic PNS are usually associated with other PNS, such as encephalomyelitis and sensory neuropathy; however, autonomic symptoms may rarely manifest as PNS symptoms. Autonomic symptoms, therefore, may be overlooked in patients with cancer.Case presentationWe described a 65-year-old Japanese man who was diagnosed with autonomic PNS due to small-cell lung carcinoma (SCLC) with Eastern Cooperative Oncology Group (ECOG) performance status 3, who suffered from orthostatic hypotension, and urinary retention needing a urethral balloon. Laboratory studies showed decreased levels of noradrenaline, and were positive for anti-ganglionic acetylcholine receptor antibody, type 1 antineuronal nuclear antibody, and sry-like high mobility group box 1 antibody. Nerve conduction evaluations and 123I-metaiodobenzylguanidine myocardial scintigraphy showed no abnormalities. Abdominal contrast-enhanced computed tomography revealed marked colonic distention. The patient’s autonomic symptoms resolved following integrated treatment (symptomatic treatment, immunotherapy, and additional chemotherapy) enabling the patient to walk, remove the urethral balloon, and endure further chemotherapy. ECOG performance status remained at 1, 10 months after admission.ConclusionsIntegrated treatment for autonomic PNS may improve autonomic symptoms and ECOG performance status of patients with cancer.

show abstract

Autoantibody Testing in Peripheral Neuropathy

Pestronk

2013

Neuromuscular Disorders in Clinical Practice

View full text Add to dashboard Cite

SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes

Cited by 40 publications

References 15 publications

Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome

Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome

Integrated treatment for autonomic paraneoplastic syndrome improves performance status in a patient with small lung cell carcinoma: a case report

Autoantibody Testing in Peripheral Neuropathy

Contact Info

Product

Resources

About